Promising new combo offers hope for rare, aggressive ovarian cancer
NCT ID NCT04602377
First seen Jan 06, 2026 · Last updated Jun 17, 2026 · Updated 27 times
Summary
This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy can improve outcomes for people with a rare and aggressive ovarian cancer called small cell ovarian carcinoma of hypercalcemic type. The trial aims to increase the chance of complete remission and allow more patients to receive intensive chemotherapy. About 27 participants aged 12 and older with untreated disease will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL OVARIAN CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Limoges - Hôpital Dupuytren
RECRUITINGLimoges, 87042, France
Contact
-
Centre Georges François Leclerc
ACTIVE_NOT_RECRUITINGDijon, 21079, France
-
Centre Hospitalier Régional Universitaire de Besançon
ACTIVE_NOT_RECRUITINGBesançon, 25030, France
-
Centre Hospitalier Universitaire d'Angers
ACTIVE_NOT_RECRUITINGAngers, 49933, France
-
Centre Léon Bérard
RECRUITINGLyon, 69373, France
Contact
-
Centre Oscar Lambret
ACTIVE_NOT_RECRUITINGLille, 59020, France
-
Gustave Roussy
RECRUITINGVillejuif, 94805, France
Contact
-
Hôpital de Hautepierre
NOT_YET_RECRUITINGStrasbourg, France
Contact
-
ICANS - Institut de cancérologie Strasbourg Europe
RECRUITINGStrasbourg, 67033, France
Contact
-
ICM Val d'Aurelle
WITHDRAWNMontpellier, 34298, France
-
ICO - Paul Papin
RECRUITINGAngers, 49055, France
Contact
-
Institut Bergonié
ACTIVE_NOT_RECRUITINGBordeaux, 33076, France
-
Oncopole Claudius Regaud - IUCT Oncopole
RECRUITINGToulouse, 31059, France
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.